New England Journal of Medicine· 2014Q1

Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia

Richard R. Furman, Jeff P. Sharman, Steven Coutré, Bruce D. Cheson et al.

1,690citations
Q1SCImago
2014year

Short summary

Combining idelalisib with rituximab significantly improved progression-free survival (not reached vs. 5.5 months), overall response rate (81% vs. 13%), and 12-month overall survival (92% vs. 80%) in relapsed CLL patients unable to tolerate standard chemotherapy.

AI-generated from the title and abstract; the full text is not read.

TakeawaysIn the app

Key pointsIn the app

Ask the paperIn the app

The rest is in the Pofolia app

Takeaways, key points and questions to the paper; new summaries every day for your field. Free.

Get it on Google Play Download on the App Store

Field: Genetics

GeneticsMedicine